Core Viewpoint - Sernova Biotherapeutics is making significant progress in its mission to develop a functional cure for type 1 diabetes (T1D) through its innovative Cell Pouch Bio-hybrid Organ technology, while also undergoing leadership changes and pursuing financing opportunities [1][3]. Company Developments - Jonathan Rigby has been appointed as Interim Chair of the board of directors, effective immediately, while the company searches for a new independent director to take on the Chair role [1]. - The company is actively engaged in financing discussions with GoldTrack Ventures and the Kingdom of Saudi Arabia, which are seen as promising partnerships [2]. - Sernova has released encouraging clinical data and formed a Clinical Advisory Board, indicating progress in its strategic and operational initiatives [3]. - The departure of Modestus Obochi, the Chief Business Officer, has been announced, with the company expressing gratitude for his contributions [3]. Technology and Innovation - Sernova is focused on developing regenerative medicine therapeutics that combine its Cell Pouch with human donor cells or stem-cell derived islet-like clusters, in collaboration with Evotec, to create Bio-hybrid Organs aimed at treating T1D and thyroid disorders [4].
Sernova Appoints Jonathan Rigby as Interim Chair